Vion Pharmaceuticals, Inc.

From Wikipedia, the free encyclopedia

Vion Pharmaceuticals, Inc. (NASDAQ: VION) is a Connecticut based pharmaceutical company founded in March 1992 to commercialize several discoveries made in the biomedical laboratories at Yale University. Vion has been a publicly traded company on NASDAQ since 1995.

[edit] Clinical Development

Several anticancer programs are underway at Vion. Two small molecules, Cloretazine (VNP40101M) and Triapine, are in human clinical trials. Cloretazine (VNP40101M), a novel alkylating agent, is in a Phase 3 trial in relapsed acute myelogenous leukemia (AML) and a Phase 2 trial in elderly de novo poor-risk AML. In addition, trials of Cloretazine (VNP40101M) are underway in pediatric brain tumors, small cell lung cancer, and advanced hematologic malignancies. Triapine, a ribonucleotide reductase inhibitor, is being evaluated in clinical trials sponsored by the National Cancer Institute.